MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively,…